Evaluation of a Selection of Lipid Profile and Kidney Function in Hypertensive Patients in Ramadi City, Western Iraq.

Section: Article
Issue
Vol. 35 No. 1 (2026): Volume 35, Issue 1
Published
Jan 1, 2026
Pages
65-74

Abstract

The most common modifiable cardiovascular disease (CVD) risk element is hypertension, and CVD has a wide variety of conditions that include coronary artery disease, heart failure, cerebrovascular accidents, myocardial infarction, atrial fibrillation and peripheral arterial disease, among chronic kidney disease or CKD and cognitive impairment. Hypertension is the leading cause of death and disability worldwide. This cross-sectional research carried out in Ramadi, Iraq, assessed 50 cases of hypertension and 25 healthy individuals to determine the demographic trends, biochemical indicators, and cardiovascular risk factors. The prevalence of hypertension was diagnosed higher in women (68%) than in men (32%), and most common in the age category of 50 60 (56%), as compared to the regional trends of ageing. There was a high hereditary connection whereby 68 per cent of the patients claimed a family history of hypertension. Blood pressure measures showed that systolic pressure (16.72 ± 1.70 mmHg vs. 11.50± 0.65 mmHg) and diastolic pressure (9.89± 1.15 mmHg vs. 7.68± 0.61 mmHg) highly increased in the patients compared with experiences of controls (P < 0.0001). Biochemical studies have revealed an increased amount of uric acid in hypertensive patients (5.28 ± 1.35 mg/dL vs. 3.94 ± 0.52 mg/dL) but not of urea. The results highlight how genetic, metabolic, and lifestyle influencing factors are interconnected in causing hypertension in western Iraq and the importance of monitoring uric acid levels, controlling lipids, and the need to have targeted community health promotion programs to aid in reducing cardiovascular risks.

References

  1. K. T. Mills et al., “Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries,” Circulation, vol. 134, no. 6, pp. 441–450, Aug. 2016, doi: 10.1161/CIRCULATIONAHA.115.018912.
  2. S. Oparil et al., “Hypertension,” Nature Reviews Disease Primers, vol. 4, art. no. 18014, Mar. 22 2018, doi: 10.1038/nrdp.2018.14.
  3. G. B. Ehret et al., “The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals,” Nature Genetics, vol. 48, no. 10, pp. 1171–1184, Oct. 2016, doi: 10.1038/ng.3667.
  4. R. P. Lifton, A. G. Gharavi, and D. S. Geller, “Molecular mechanisms of human hypertension,” Cell, vol. 104, no. 4, pp. 545–556, Feb. 23 2001, doi: 10.1016/S0092-8674(01)00241-0.
  5. D. I. Feig, D. H. Kang, and R. J. Johnson, “Uric acid and cardiovascular risk,” New England Journal of Medicine, vol. 359, no. 17, pp. 1811–1821, Oct. 23 2008, doi: 10.1056/NEJMra0800885.
  6. S. M. Grundy, "Metabolic syndrome update," Trends Cardiovasc Med, vol. 26, no. 4, pp. 364–373, May 2016, doi: 10.1016/j.tcm.2015.10.004.
  7. S. P. Pinney, A. Anyanwu, A. Lala, J. Teuteberg, N. Uriel, and M. J. J. O. T. A. C. O. C. Mehra, "Left Ventricular Assist Devices for Lifelong Support (vol 69, pg 2845, 2017)," J. Am. Coll. Cardiol., vol. 70, no. 10, p. 1308, 2017, doi: 10.1016/j.jacc.2017.04.031.
  8. C. Okulmus, N. I. Icil, O. Turkyilmaz, and Z. T. J. C. C. P. Yildirir, "Clinical chemistry reference intervals for swiss albino strain mice commonly used in scientific studies," Compar. Clin. Pathol., vol. 2025, pp. 1–8, 2025.
  9. A. Hazra and N. Gogtay, "Biostatistics Series Module 4: Comparing Groups - Categorical Variables," Indian J. Dermatol., vol. 61, no. 4, pp. 385–392, Jul.–Aug. 2016, doi: 10.4103/0019-5154.185700.
  10. J. F. Reckelhoff, "Gender differences in the regulation of blood pressure," Hypertension, vol. 37, no. 5, pp. 1199–1208, May 2001, doi: 10.1161/01.hyp.37.5.1199.
  11. R. Lima, M. Wofford, and J. F. Reckelhoff, "Hypertension in postmenopausal women," Curr Hypertens Rep., vol. 14, no. 3, pp. 254–260, Jun. 2012, doi: 10.1007/s11906-012-0252-8.
  12. L. Trtica Majnarić, I. Martinović, Š. Šabanović, S. Rudan, F. Babič, and T. Wittlinger, "The effect of hypertension duration and the age of onset on CV risk factors expression in perimenopausal women," Int. J. Hypertens., vol. 2019, p. 9848125, 2019, doi: 10.1155/2019/9848125.
  13. T. M. Spruill, "Chronic psychosocial stress and hypertension," Curr Hypertens Rep., vol. 12, no. 1, pp. 10–16, Feb. 2010, doi: 10.1007/s11906-009-0084-8.
  14. S. S. Franklin et al., "Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study," Circulation, vol. 96, no. 1, pp. 308–315, Jul. 1 1997, doi: 10.1161/01.cir.96.1.308.
  15. E. G. Lakatta and D. J. C. Levy, "Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a 'set up' for vascular disease," Circulation, vol. 107, no. 1, pp. 139–146, 2003, doi: 10.1161/01.CIR.0000048892.83500.58.
  16. A. V. Chobanian et al., "Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure," Hypertension, vol. 42, no. 6, pp. 1206–1252, Dec. 2003, doi: 10.1161/01.HYP.0000107251.49515.c2.
  17. P. K. Whelton et al., "2017 ACC/AHA Guideline for High Blood Pressure in Adults: Executive Summary," Hypertension, vol. 71, no. 6, pp. 1269–1324, Jun. 2018, doi: 10.1161/HYP.0000000000000066.
  18. T. H. Jafar et al., “Integration of a multicomponent intervention for hypertension into primary healthcare services in Singapore: A cluster randomized controlled trial,” PLoS Medicine, vol. 19, no. 6, p. e1004026, Jun. 2022. doi: 10.1371/journal.pmed.1004026
  19. W. B. Kannel, T. Gordon, and M. J. Schwartz, “Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham study,” Am. J. Cardiol., vol. 27, no. 4, pp. 335–346, Apr. 1971. doi: 10.1016/0002-9149(71)90428-0
  20. G. Parati et al., “Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension,” J. Hypertens., vol. 39, no. 9, pp. 1742–1767, Sep. 2021. doi: 10.1097/HJH.0000000000002922
  21. L. Du et al., “Hyperuricemia and its related diseases: mechanisms and advances in therapy,” Signal Transduct. Target. Ther., vol. 9, no. 1, p. 212, Aug. 2024. doi: 10.1038/s41392-024-02002-9
  22. A. Mihalache, L. Garneata, C. A. Mocanu, T.-P. Simionescu, and G. Mircescu, “Low-salt low-protein diet and blood pressure control in patients with advanced diabetic kidney disease and heavy proteinuria,” Int. Urol. Nephrol., vol. 53, no. 6, pp. 1197–1207, Jun. 2021. doi: 10.1007/s11255-020-02696-6
  23. S. Udani, I. Lazich, and G. L. Bakris, “Epidemiology of hypertensive kidney disease,” Nat. Rev. Nephrol., vol. 7, no. 1, pp. 11–21, Jan. 2011. doi: 10.1038/nrneph.2010.154
  24. C. Borghi, F. Fogacci, D. Agnoletti, and A. F. G. Cicero, “Hypertension and dyslipidemia combined therapeutic approaches,” High Blood Press. Cardiovasc. Prev., vol. 29, no. 3, pp. 221–230, May 2022. doi: 10.1007/s40292-022-00519-x
  25. X. Hou et al., “Joint modifiable risk factor control and incident stroke in hypertensive patients,” J. Clin. Hypertens. (Greenwich), vol. 26, no. 11, pp. 1274–1283, Nov. 2024. doi: 10.1111/jch.14836

Authors

Othman Mueen Mohammed

Department of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Al Anbar, Iraq

Haitham L. Abdulhadi

Department of Biology, College of Education for Pure Sciences, University of Anbar, Ramadi, Iraq

Identifiers

https://doi.org/10.33899/jes.v35i1.60278
Download this PDF file
PDF

Statistics

Downloads

Download data is not yet available.

How to Cite

[1]
O. M. Mohammed and H. L. . Abdulhadi, “ Western Iraq”., JES, vol. 35, no. 1, pp. 65–74, Jan. 2026.
Copyright and Licensing
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.